C-type natriuretic peptide (CNP) and postnatal linear growth

Handbook of Growth and Growth Monitoring in Health and Disease

Volumn , Issue , 2012, Pages 2789-2809

  Prickett, Timothy C R ^a   Espiner, Eric A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862139003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-1795-9_166     Document Type: Chapter

References (56)

1. Acuff CG, Huang H, Steinhelper ME. Estradiol induces C-type natriuretic peptide gene expression in mouse uterus. Am J Physiol. 1997;273:H2672-7.
2. Agoston H, Khan S, James CG, Gillespie JR, Serra R, Stanton LA, Beier F. C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways. BMC Dev Biol. 2007;7:18.
3. Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI, Kant S, Cole T, Morton J, Cormier-Daire V, Faivre L, Lees M, Kirk J, Mortier GR, Leroy J, Zabel B, Kim CA, Crow Y, Braverman NE, van den Akker F, Warman ML. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet. 2004;75:27-34.
4. Bocciardi R, Giorda R, Buttgereit J, Gimelli S, Divizia MT, Beri S, Garofalo S, Tavella S, Lerone M, Zuffardi O, Bader M, Ravazzolo R, Gimelli G. Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum Mutat. 2007;28:724-31.
5. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227-34.
6. Chikuda H, Kugimiya F, Hoshi K, Ikeda T, Ogasawara T, Shimoaka T, Kawano H, Kamekura S, Tsuchida A, Yokoi N, Nakamura K, Komeda K, Chung UI, Kawaguchi H. Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes. Genes Dev. 2004;18:2418-29.
7. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y, Itoh H, Tanaka K, Saito Y, Katsuki M. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA. 2001;98:4016-21.
8. Espiner EA, Richards AM, Yandle TG, Nicholls MG. Natriuretic hormones. Endocrinol Metab Clin North Am. 1995;24:481-509.
9. Espiner EA, Prickett TC, Yandle TG, Barrell GK, Wellby M, Sullivan MJ, Darlow BA. ABCs of natriuretic peptides:growth. Horm Res. 2007;67 Suppl 1:81-90.
10. Estrada K, Krawczak M, Schreiber S, van Duijn K, Stolk L, van Meurs JB, Liu F, Penninx BW, Smit JH, Vogelzangs N, Hottenga JJ, Willemsen G, de Geus EJ, Lorentzon M, von Eller-Eberstein H, Lips P, Schoor N, Pop V, de Keijzer J, Hofman A, Aulchenko YS, Oostra BA, Ohlsson C, Boomsma DI, Uitterlinden AG, van Duijn CM, Rivadeneira F, Kayser M. A genome-wide association study of northwestern Europeans involves the CNP signaling pathway in the etiology of human height variation. Hum Mol Genet. 2009;18:3516-24.
11. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;177:927-31.
12. Hagiwara H, Inoue A, Yamaguchi A, Yokose S, Furuya M, Tanaka S, Hirose S. cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol Cell Physiol. 1996;270:C1311-8.
13. Jaubert J, Jaubert F, Martin N, Washburn LL, Lee BK, Eicher EM, Guenet JL. Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci USA. 1999;96:10278-83.
14. Jiao Y, Yan J, Jiao F, Yang H, Donahue LR, Li X, Roe BA, Stuart J, Gu W. A single nucleotide mutation in Nppc is associated with a long bone abnormality in lbab mice. BMC Genet. 2007;8:16.
15. Kishimoto I, Tokudome T, Horio T, Soeki T, Chusho H, Nakao K, Kangawa K. C-type natriuretic peptide is a Schwann cell-derived factor for development and function of sensory neurones. J Neuroendocrinol. 2008;20:1213-23.
16. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, Wilcox WR. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005;118:5089-100.
17. Langenickel TH, Buttgereit J, Pagel-Langenickel I, Lindner M, Monti J, Beuerlein K, Al-Saadi N, Plehm R, Popova E, Tank J, Dietz R, Willenbrock R, Bader M. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA. 2006;103:4735-40.
18. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5:599-606.
19. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA. 1999;96:7403-8.
20. McNeill BA, Barrell GK, Wellby M, Prickett TC, Yandle TG, Espiner EA. C-type natriuretic peptide forms in pregnancy: maternal plasma profiles during ovine gestation correlate with placental and fetal maturation. Endocrinology. 2009;150:4777-83.
21. Moffatt P, Thomas G, Sellin K, Bessette MC, Lafreniere F, Akhouayri O, St-Arnaud R, Lanctot C. Osteocrin is a specific ligand of the natriuretic peptide clearance receptor that modulates bone growth. J Biol Chem. 2007;282:36454-62.
22. Moncla A, Missirian C, Cacciagli P, Balzamo E, Legeai-Mallet L, Jouve JL, Chabrol B, Le Merrer M, Plessis G, Villard L, Philip N. A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype. Hum Mutat. 2007;28:1183-8.
23. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J. The role of liver-derived insulin-like growth factor-I. Endocr Rev. 2009;30:494-535.
24. Olney RC, Bukulmez H, Bartels CF, Prickett TC, Espiner EA, Potter LR, Warman ML. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab. 2006;91:1229-32.
25. Olney RC, Prickett TC, Yandle TG, Espiner EA, Han JC, Mauras N. Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: effects of puberty, testosterone and growth hormone. J Clin Endocrinol Metab. 2007;92:4294-8.
26. Olney RC, Permuy JW, Prickett TC, Espiner EA. Amino-terminal C-type natriuretic peptide (NTproCNP) levels in healthy children; a longitudinal study. Proceedings of the Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY; 2009a.
27. Olney RC, Prickett TC, Espiner EA, Arn PH, Upp HLH, Zerah MM, Dietz HC. Is C-type natriuretic peptide (CNP) production elevated in Marfan syndrome? Proceedings of the Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY; 2009b.
28. Palmer SC, Prickett TC, Espiner EA, Yandle TG, Richards AM. Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension. 2009;54:612-18.
29. Pfeifer A, Aszodi A, Seidler U, Ruth P, Hofmann F, Fassler R. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science. 1996;274:2082-6.
30. Prickett TCR, Yandle TG, Nicholls MG, Espiner EA, Richards AM. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun. 2001;286:513-7.
31. Prickett TCR, Kaaja RJ, Nicholls MG, Espiner EA, Richards AM, Yandle TG. N-terminal pro-C-type natriuretic peptide, but not C-type natriuretic peptide, is greatly elevated in the fetal circulation. Clin Sci. 2004a;106:535-40.
32. Prickett T, Yandle T, Espiner E, Barrell G, Richards A. First identification of Aminoterminal C-type natriuretic peptide in growth plates of long bones. 12th International Congress of Endocrinology (Lisbon): 2004b.
33. Prickett TC, Barrell GK, Wellby M, Yandle TG, Richards AM, Espiner EA. Response of plasma CNP forms to acute anabolic and catabolic interventions in growing lambs. Am J Physiol Endocrinol Metab. 2007a;292:E1395-400.
34. Prickett TC, Rumball CW, Buckley AJ, Bloomfield FH, Yandle TG, Harding JE, Espiner EA. C-type natriuretic peptide forms in the ovine fetal and maternal circulations: evidence for independent regulation and reciprocal response to undernutrition. Endocrinology. 2007b;148:4015-22.
35. Prickett TC, Barrell GK, Wellby M, Yandle TG, Richards AM, Espiner EA. Effect of sex steroids on plasma C-type natriuretic peptide forms: stimulation by oestradiol in lambs and adult sheep. J Endocrinol. 2008a;199:481-7.
36. Prickett TCR, Lynn AM, Barrell GK, Darlow BA, Cameron VA, Espiner EA, Richards AM, Yandle TG. Aminoterminal proCNP: a putative marker of cartilage activity in postnatal growth. Pediatr Res. 2005;58:334-40.
37. Prickett TCR, Dixon B, Frampton C, Yandle TG, Richards AM, Espiner EA, Darlow BA. Plasma aminoterminal pro C-type natriuretic peptide in the neonate: relation to gestational age and post natal linear growth. J Clin Endocrinol Metab. 2008b;93:225-32.
38. Prickett TC, Charles CJ, Yandle TG, Richards AM, Espiner EA. Skeletal contributions to plasma CNP forms: evidence from regional sampling in growing lambs. Peptides. 2009;30:2343-7.
39. Prickett TCR, Ryan JF, Wellby W, Barrell GK, Yandle TG, Richards AM, Espiner EA. Effect of nutrition on plasma CNP forms in adult sheep; evidence for enhanced CNP degradation during caloric restriction. Metabolism. 2010;59:796-801.
40. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Hogler W. Sex-and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92:443-9.
41. Sogawa C, Tsuji T, Shinkai Y, Katayama K, Kunieda T. Short-limbed dwarfism: slw is a new allele of Npr2 causing chondrodysplasia. J Hered. 2007;98:575-80.
42. Southern Reh CM, Azen C, Espiner EA, Olney RC, Prickett TC, May JA, Geffner ME. Plasma CNP forms in prepubertal children with acquired thyroid disease: correlation with thyroid status and height velocity. Proceedings of the Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY; 2009.
43. Suda M, Tanaka K, Fukushima M, Natsui K, Yasoda A, Komatsu Y, Ogawa Y, Itoh H, Nakao K. C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Biochem Biophys Res Commun. 1996;223:1-6.
44. Suda M, Ogawa Y, Tanaka K, Tamura N, Yasoda A, Takigawa T, Uehira M, Nishimoto H, Itoh H, Saito Y, Shiota K, Nakao K. Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc Natl Acad Sci USA. 1998;95:2337-42.
45. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Invest. 1992;90:1145-9.
46. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97:4239-44.
47. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci USA. 2004;101:17300-5.
48. Tsuji T, Kunieda T. A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem. 2005;280:14288-92.
49. van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev. 2003;24:782-801.
50. Woods A, Khan S, Beier F. C-type natriuretic peptide regulates cellular condensation and glycosaminoglycan synthesis during chondrogenesis. Endocrinology. 2007;148:5030-41.
51. Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem. 2003;278:25847-52.
52. Yamashita Y, Takeshige K, Inoue A, Hirose S, Takamori A, Hagiwara H. Concentration of mRNA for the natriuretic peptide receptor-C in hypertrophic chondrocytes of the fetal mouse tibia. J Biol Chem. 2000;127:177-9.
53. Yandle TG. Biochemistry of natriuretic peptides. J Intern Med. 1994;235:561-76.
54. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med. 2004;10:80-6.
55. Yasoda A, Kitamura H, Fujii T, Kondo E, Murao N, Miura M, Kanamoto N, Komatsu Y, Arai H, Nakao K. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology. 2009;150:3138-44.
56. Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA. 1997;94:13215-20.